LGC Clinical Diagnostics’ Post

View organization page for LGC Clinical Diagnostics, graphic

3,436 followers

In this month's Science Spotlight, a team from Germany validated the TruSight Oncology 500 ctDNA assay using reference and patient samples, including Seraseq® ctDNA Reference Material v2 AF1% and Seraseq® ctDNA Reference Material v2 AF0.5%. They demonstrated high sensitivity and low variant detection variability of the assay for SNVs, insertions, deletions and fusions down to a VAF of 0.5% in the reference samples, and the VAFs were concordant with previous dPCR results in patient samples. Interestingly, the sensitivity and variability were dependent on the reference material used, with the Seraseq® ctDNA reference materials resulting in much lower variability and better reported sensitivity. Read the full article here to learn more about their findings! https://hubs.ly/Q02plqvh0 #ScienceSpotlight

  • No alternative text description for this image

This study sheds valuable light on the validation of the TruSight Oncology 500 ctDNA assay, particularly in its sensitivity and variability for detecting various mutations. The dependency on reference materials, as highlighted here, underscores the importance of meticulous validation procedures in molecular diagnostics. Such insights contribute significantly to advancing precision medicine and improving patient care.

To view or add a comment, sign in

Explore topics